The following information is intended for use by Health Care Professionals of the United States only. Countries outside of the United States may have regulatory requirements or medical practices that are different from those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.
Prevnar® is included on the Recommended Childhood and Adolescent Immunization Schedule approved by the Advisory Committee on Immunization Practices, the American Academy of Family Physicians, and the American Academy of Pediatrics.2
Prevnar® is indicated for active immunization of infants and toddlers against invasive disease caused by
Streptococcus pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F). The
routine schedule is 2, 4, 6, and 12 to 15 months of age. For previously unvaccinated infants and children
7 months of age, please
see Prescribing Information for appropriate dosing
schedule.1
Prevnar® is supplied as ready-to-use prefilled syringes (10 x 0.5-mL prefilled syringes per package).1
Prevnar® is stored at refrigerated temperatures of 2ºC to 8ºC (36ºF to 46ºF) away from freezer compartment. DO NOT FREEZE.1
Important
Safety Information
In clinical trials (n=18,168), the most frequently reported adverse events included injection site reactions, fever
(38ºC/100.4ºF), irritability,
drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, and rash.
Risks are associated with all vaccines, including Prevnar®. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. Prevnar® does not provide 100% protection against vaccine serotypes or protect against nonvaccine serotypes.
Please see Prescribing Information.
